CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Abstract Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Patient derived colorectal cancer organ...

Full description

Bibliographic Details
Main Authors: Reyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, Khurum Khan, Louise J. Barber, Andrew Woolston, Georgia Spain, Katharina von Loga, Ben Challoner, Radhika Patel, Michael Ranes, Amanda Swain, Janet Thomas, Annette Bryant, Claire Saffery, Nicos Fotiadis, Sebastian Guettler, David Mansfield, Alan Melcher, Thomas Powles, Sheela Rao, David Watkins, Ian Chau, Nik Matthews, Fredrik Wallberg, Naureen Starling, David Cunningham, Marco Gerlinger
Format: Article
Language:English
Published: BMJ Publishing Group 2019-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cibisatamab
CEA
Immunotherapy
Patient-derived organoids
WNT/β-catenin
Online Access:http://link.springer.com/article/10.1186/s40425-019-0575-3

Internet

http://link.springer.com/article/10.1186/s40425-019-0575-3

Similar Items